| 1 |
Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease
Abhirup Mandal, Vrinda Gote, Dhananjay Pal et al. · Pharmaceutical Research
|
7 Jan 2019 |
157 |
| 2 |
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease
Damien F. Goldberg, Ranjan P. Malhotra, Barry A. Schechter et al. · Ophthalmology
Open access |
6 Apr 2019 |
110 |
| 3 |
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Brett King, Maryanne Makredes Senna, Natasha Atanaskova Mesinkovska et al. · Journal of the American Academy of Dermatology
Open access |
23 Jul 2024 |
101 |
| 4 |
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*
Diamant Thaçi, Stefano Piaserico, Richard Bruce Warren et al. · British Journal of Dermatology
Open access |
8 Feb 2021 |
101 |
| 5 |
MR-guided Focused Ultrasound Facilitates Sonodynamic Therapy with 5-Aminolevulinic Acid in a Rat Glioma Model
Sheng‐Kai Wu, Marc A. Santos, Stuart L. Marcus et al. · Scientific Reports
Open access |
18 Jul 2019 |
93 |
| 6 |
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
Philip J. Mease, Saima Chohan, Ferran José García Fructuoso et al. · Annals of the Rheumatic Diseases
Open access |
13 May 2021 |
87 |
| 7 |
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
Andrew Blauvelt, Howard L. Sofen, Kim Alexander Papp et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
13 Aug 2019 |
59 |
| 8 |
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
Darrell E White, Yang Zhao, Abayomi Ogundele et al. · Clinical ophthalmology
Open access |
Nov 2019 |
53 |
| 9 |
Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm
Glenn A. Van Buskirk et al. · AAPS PharmSciTech
Open access |
27 Feb 2014 |
44 |
| 10 |
Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
Darrell E White, Yang Zhao, Hemalatha Jayapalan et al. · Clinical ophthalmology
Open access |
Mar 2020 |
42 |
| 11 |
Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial
Josbert M. Metselaar, Leonie M. Middelink, Cornelis H. Wortel et al. · Journal of Controlled Release
|
9 Dec 2021 |
38 |
| 12 |
Randomized Vehicle-Controlled Study of Short Drug Incubation Aminolevulinic Acid Photodynamic Therapy for Actinic Keratoses of the Face or Scalp
David M. Pariser, Anna Houlihan, Mary Beth Ferdon et al. · Dermatologic Surgery
Open access |
10 Feb 2016 |
36 |
| 13 |
Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease
Ryan R. Walsh, Nitin K. Damle, Sanjay N. Mandhane et al. · Parkinsonism & Related Disorders
Open access |
13 Jan 2023 |
34 |
| 14 |
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies
Ranjan P. Malhotra, Douglas K. Devries, Jodi Luchs et al. · Cornea
Open access |
10 Jul 2019 |
33 |
| 15 |
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
Mark Lebwohl, Craig L. Leonardi, Nehal N. Mehta et al. · Journal of the American Academy of Dermatology
Open access |
19 Sep 2020 |
28 |
| 16 |
Effect of Steady-State Atorvastatin on the Pharmacokinetics of a Single Dose of Colchicine in Healthy Adults Under Fasted Conditions
Matthew W. Davis, Suman Wason · Clinical Drug Investigation
|
22 Jan 2014 |
28 |
| 17 |
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
Ralf Gutzmer, Carmen Loquai, Caroline Robert et al. · Dermatology and Therapy
Open access |
6 Sep 2021 |
26 |
| 18 |
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis
Yves P. Poulin, M. Ramon, L.A. Rosoph et al. · Journal of the European Academy of Dermatology and Venereology
|
10 Jan 2020 |
25 |
| 19 |
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2
Anthony Patrick Fernandez, Esteban Daudén, Sascha Gerdes et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
23 Apr 2022 |
24 |
| 20 |
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis
Ralf Gutzmer, Caroline Robert, Carmen Loquai et al. · BMC Cancer
Open access |
19 Nov 2021 |
24 |
| 21 |
The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
Cynthia Matossian, Xue Song, Ishveen Chopra et al. · Clinical ophthalmology
Open access |
Oct 2020 |
23 |
| 22 |
Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial
John T. Lear, Axel Hauschild, Eggert Stockfleth et al. · Clinical Cosmetic and Investigational Dermatology
Open access |
Feb 2020 |
23 |
| 23 |
Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme
K. Haycraft, D. DiRuggiero, Stephen J. Rozzo et al. · British Journal of Dermatology
|
29 Jan 2020 |
22 |
| 24 |
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
John D. Sheppard, Paul C. Cockrum, Angela Justice et al. · Ophthalmology and Therapy
Open access |
14 May 2018 |
22 |
| 25 |
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study
Kurt Gebauer, Lynda J. Spelman, Paul Steven Yamauchi et al. · Journal of the American Academy of Dermatology
Open access |
28 Mar 2024 |
21 |
| 26 |
Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial
Karl D. Lewis, Reinhard Dummer, Aaron S. Farberg et al. · Dermatology and Therapy
Open access |
20 Oct 2021 |
21 |
| 27 |
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
Kenneth B. Gordon, Kristian Reich, Jeffrey Crowley et al. · Journal of Dermatological Treatment
Open access |
30 Apr 2020 |
21 |
| 28 |
Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
Darrell E White, Yang Zhao, Hemalatha Jayapalan et al. · Clinical ophthalmology
Open access |
Mar 2020 |
21 |
| 29 |
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials
Robert John Smyth-Medina, Josh Johnston, Douglas K. Devries et al. · Journal of Ocular Pharmacology and Therapeutics
|
2 Aug 2019 |
19 |
| 30 |
Nucleic Acid Bioconjugates in Cancer Detection and Therapy
Pradeepkumar L. Patel, Niki K. Rana, Mayurbhai R. Patel et al. · ChemMedChem
|
10 Dec 2015 |
19 |
| 31 |
One-pot quantitative hydrolysis of lignocelluloses mediated by black liquor
Zuolin Zhu, Zuolin Zhu, Meg M. Sun et al. · Bioresource Technology
|
26 Oct 2012 |
19 |
| 32 |
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
John D. Sheppard, Mark T. Bergmann, Barry A. Schechter et al. · Clinical ophthalmology
Open access |
2021 |
18 |
| 33 |
Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months
Reinhard Dummer, John T. Lear, Alex D. Guminski et al. · Journal of the American Academy of Dermatology
Open access |
24 Dec 2020 |
18 |
| 34 |
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
Mark Lebwohl, Craig L. Leonardi, Nehal N. Mehta et al. · Journal of the American Academy of Dermatology
Open access |
26 Sep 2019 |
18 |
| 35 |
Development and Validation of Liquid Chromatographic and UV Derivative Spectrophotometric Methods for the Determination of Famciclovir in Pharmaceutical Dosage Forms
Srinubabu Gedela, B. Sudharani, L. Sridhar et al. · Chemical and Pharmaceutical Bulletin
Open access |
2006 |
18 |
| 36 |
Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis
Mark Lebwohl, André Lopes Carvalho, Akihiko Asahina et al. · Dermatology and Therapy
ReviewOpen access |
6 May 2025 |
17 |
| 37 |
Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
Shinichi Imafuku, Hidemi Nakagawa, Atsuyuki Igarashi et al. · The Journal of Dermatology
Open access |
Feb 2021 |
17 |
| 38 |
Efficacy of aminolevulinic acid 20 % solution photodynamic therapy in the treatment of actinic keratoses on the upper extremities: A post hoc analysis of a phase 3, randomized, vehicle-controlled trial
Brian Berman, Neal D Bhatia, Daniel J. Piacquadio et al. · Photodiagnosis and Photodynamic Therapy
Open access |
15 Sep 2020 |
17 |
| 39 |
Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status
Steven R. Feldman, Jingchuan Zhang, Diane Martinez et al. · Journal of Dermatological Treatment
Open access |
26 Nov 2019 |
16 |
| 40 |
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
Athanasios Tsianakas, Thierry Passeron, Nina Magnolo et al. · Journal of the American Academy of Dermatology
Open access |
28 Nov 2025 |
15 |
| 41 |
The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies
Melissa Morrison Toyos, Preeya K. Gupta, Brittany M. Mitchell et al. · Current Eye Research
Open access |
29 Aug 2021 |
14 |
| 42 |
Gene Set Enrichment Analsyes Identify Pathways Involved in Genetic Risk for Diabetic Retinopathy
Lucia Sobrin et al. · American Journal of Ophthalmology
Open access |
21 Jun 2021 |
14 |
| 43 |
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
Steven R. Feldman, Joseph Frank Merola, David M. Pariser et al. · Journal of Dermatological Treatment
Open access |
8 Mar 2021 |
14 |
| 44 |
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
Atsuyuki Igarashi, Hidemi Nakagawa, Akimichi Morita et al. · The Journal of Dermatology
Open access |
25 Feb 2021 |
14 |
| 45 |
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Boni Elizabeth Elewski, Alan Menter, Jeffrey Crowley et al. · Journal of Dermatological Treatment
|
3 Jul 2019 |
14 |
| 46 |
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
Paul M Karpecki, Victoria E. Barghout, Brad Schenkel et al. · BMC Ophthalmology
Open access |
2 Nov 2023 |
13 |
| 47 |
Assessment of Efficacy and Safety of Arterolane Maleate–Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa
Offianan André Touré et al. · Clinical Infectious Diseases
|
Aug 2017 |
13 |
| 48 |
SITE SPECIFIC DRUG DELIVERY THROUGH NASAL ROUTE USING BIOADHESIVE POLYMERS
Devesh U. Kapoor, Manish P. Patel, Ruchi B Vyas et al. · Journal of Drug Delivery and Therapeutics
Open access |
15 Jan 2015 |
13 |
| 49 |
Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis
Neal D Bhatia, Jayme Heim, Brad Schenkel et al. · Journal of Dermatological Treatment
Open access |
11 May 2023 |
12 |
| 50 |
Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data
Jerry Bagel, Brad P. Glick, Jashin J. Wu et al. · Journal of Medical Economics
Open access |
2021 |
12 |